These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1226 related articles for article (PubMed ID: 29208565)

  • 21. Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status.
    Ahtiainen M; Wirta EV; Kuopio T; Seppälä T; Rantala J; Mecklin JP; Böhm J
    Mod Pathol; 2019 Jun; 32(6):866-883. PubMed ID: 30723299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer.
    Sui Q; Liu D; Jiang W; Tang J; Kong L; Han K; Liao L; Li Y; Ou Q; Xiao B; Liu G; Ling Y; Chen J; Liu Z; Zuo Z; Pan Z; Zhou P; Zheng J; Ding PR
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33782107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study.
    Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P
    Front Immunol; 2022; 13():809971. PubMed ID: 35185898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression.
    Acosta-Gonzalez G; Ouseph M; Lombardo K; Lu S; Glickman J; Resnick MB
    Hum Pathol; 2019 Jan; 83():115-123. PubMed ID: 30172913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry.
    Yan H; Li Y; Wang X; Qian J; Xu M; Peng J; Huang D
    Front Oncol; 2022; 12():867658. PubMed ID: 35669431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.
    Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A
    Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
    Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma.
    Nam SJ; Kim YH; Park JE; Ra YS; Khang SK; Cho YH; Kim JH; Sung CO
    Cancer Immunol Immunother; 2019 Feb; 68(2):305-318. PubMed ID: 30483834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer.
    Giordano G; Parcesepe P; D'Andrea MR; Coppola L; Di Raimo T; Remo A; Manfrin E; Fiorini C; Scarpa A; Amoreo CA; Conciatori F; Milella M; Caruso FP; Cerulo L; Porras A; Pancione M
    J Exp Clin Cancer Res; 2019 Jan; 38(1):28. PubMed ID: 30670049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
    Quiroga D; Lyerly HK; Morse MA
    Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
    Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
    Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tn Antigen Expression Defines an Immune Cold Subset of Mismatch-Repair Deficient Colorectal Cancer.
    Matsumoto T; Okayama H; Nakajima S; Saito K; Nakano H; Endo E; Kase K; Ito M; Yamauchi N; Yamada L; Kanke Y; Onozawa H; Fujita S; Sakamoto W; Saito M; Saze Z; Momma T; Mimura K; Kono K
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma.
    Lee LH; Cavalcanti MS; Segal NH; Hechtman JF; Weiser MR; Smith JJ; Garcia-Aguilar J; Sadot E; Ntiamoah P; Markowitz AJ; Shike M; Stadler ZK; Vakiani E; Klimstra DS; Shia J
    Mod Pathol; 2016 Nov; 29(11):1433-1442. PubMed ID: 27443512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accuracy of four mononucleotide-repeat markers for the identification of DNA mismatch-repair deficiency in solid tumors.
    Takehara Y; Nagasaka T; Nyuya A; Haruma T; Haraga J; Mori Y; Nakamura K; Fujiwara T; Boland CR; Goel A
    J Transl Med; 2018 Jan; 16(1):5. PubMed ID: 29329588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors.
    Fu Y; Yang B; Cui Y; Hu X; Li X; Lu F; Qin T; Zhang L; Hu Z; Guo E; Fan J; Xiao R; Li W; Qin X; Hu D; Peng W; Liu J; Wang B; Mills GB; Chen G; Sun C
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in the immunosurveillance pattern associated with DNA mismatch repair status between right-sided and left-sided colorectal cancer.
    Kanno H; Miyoshi H; Yoshida N; Sudo T; Nakashima K; Takeuchi M; Nomura Y; Seto M; Hisaka T; Tanaka H; Okuda K; Akagi Y; Ohshima K
    Cancer Sci; 2020 Aug; 111(8):3032-3044. PubMed ID: 32449240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.